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Abstract 
Introduction: In the clinical setting, the diagnosis of neurosarcoidosis in patients with central diabetes insipidus (CDI) is typically based 
both on symptoms (i.e. polydipsia or polyuria) and brain magnetic resonance imaging (MRI) findings (e.g. pituitary abnormality). However, 
inconsistent changes in the patient’s symptoms and brain MRI findings may occur during the clinical course of the disease.
This review was performed to summarise the relationship between symptoms and brain MRI findings in previously reported cases of 
neurosarcoidosis with CDI.
Material and methods: Case studies of patients diagnosed with neurosarcoidosis with CDI were collected via a PubMed search of studies 
published through 30 June 2018.
Results: Thirteen eligible studies were reviewed (20 patients; 12 men, 8 women; mean age 33 years). Polydipsia or polyuria was the first 
symptom in 13 patients. The mean duration from disease onset to diagnosis was 3.4 months. Brain MRIs showed abnormal findings in the 
hypothalamus and pituitary for 17 patients. Immunosuppressive drugs were used in 17 patients. For 14 patients, MRI findings improved, 
while symptoms did not.
Conclusion: Patients with both neurosarcoidosis and CDI symptoms often do not improve, despite the fact that brain MRI findings 
often improve following treatment. More studies involving detailed pathological analyses and longer follow-up periods are necessary. 
(Endokrynol Pol 2019; 70 (5): 430–437)
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Introduction 
Sarcoidosis is a multi-organ, non-caseating, granulo-
ma-forming disorder. Although its aetiology remains 
unknown, sarcoidosis is thought to be immune-medi-
ated [1]. Nervous system involvement, which can occur 
in either the central or peripheral nervous system, is 
observed in 5% to 15% of patients with sarcoidosis [2, 
3]. When the hypothalamus-pituitary axis is affected 
in patients with sarcoidosis, central diabetes insipidus 
(CDI) is generally also present [4]. CDI is rarely ob-
served, occurring in approximately 2% of patients with 
neurosarcoidosis, and presents with unique symptoms, 
such as polydipsia or polyuria [5].
Magnetic resonance imaging (MRI) with gadolinium 
is the recommended method for the initial assessment 
of neural pathologies [6]. Brain MRI can be helpful in 
patients with neurosarcoidosis, although autoimmune 
inflammatory, infectious, or malignant diseases can 
display similar MRI findings as neurosarcoidosis [7]. 
The MRI findings of neurosarcoidosis typically include 
infundibular involvement, pituitary stalk thickening, 
or pituitary gland enlargement; additionally, a loss of 
the hyperintense signal from the posterior pituitary 
on T1-weighted images is indicative of an infiltrative 
process [6].
An earlier report suggested that corticosteroid 
treatment in patients with neurosarcoidosis ef-
fectively ameliorated MRI abnormalities but failed 
to completely subdue CDI without desmopressin 
supplementation; however, this study included only 
four cases [8]. The current review of previously pub-
lished case studies was performed to summarise the 
relationship between changes in symptoms and brain 
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In the current review, complete improvement in CDI 
symptoms was not observed in most patients diagnosed 
with neurosarcoidosis with CDI, despite improvements 
in the abnormal brain MRI findings. These findings sug-
gest that inconsistent changes in symptoms and brain 
MRI findings occur in most cases during the clinical 
course of the disease, and reinforce the observation 
made in the earlier report that included a small num-
ber of cases [8]. This result has clinical implications for 
the use of MRI in the diagnosis of neurosarcoidosis in 
patients with CDI.
There are several possible reasons for the find-
ings in this review. Once the central nervous system 
has become involved in sarcoidosis, the pathological 
changes that occur in the brain may be irreversible. 
Some studies have reported improvements in the MRI 
findings for the anterior pituitary after immunosup-
pressant treatment [8, 9, 11, 16]. In particular, the 
posterior, rather than anterior, pituitary gland may 
undergo irreversible damage following granuloma 
formation. Because the distance from the base of the 
brain to the sella turcica is greater than that to the 
pituitary, there has been an assumption that sarcoid-
osis lesions cannot completely invade the anterior 
pituitary [16].
Patients with sarcoidosis typically display infun-
dibular involvement, pituitary stalk thickening, or 
pituitary gland enlargement when examined by MRI, 
and the loss of the hyperintense signal from the poste-
rior pituitary on T1-weighted images can be indicative 
of an infiltrative process [6]. Infiltration of sarcoidosis 
into the infundibulum may jeopardise the production 
and transport of pituitary-stimulating hormones and 
induce the direct involvement of the pituitary [2]. This 
infiltration process may be independent of improve-
ments in CDI symptoms.
The primary treatment option for neurosarcoidosis 
is steroid therapy [20]. Immunosuppressive agents 
and antimalarials can also be administered in resistant 
cases or when glucocorticoids are tolerated [20, 21]. In 
the current review, immunosuppressants, especially 
prednisolone, were used in most of the cases, but CDI 
did not improve, and the use of DDAVP was continued. 
One report suggested that the early administration 
(within one month of onset) of prednisolone was effec-
tive for the improvement of CDI symptoms; however, 
not all patients had posterior pituitary lesions in that 
report [22]. In the current review, the mean duration 
from disease onset to diagnosis was > 3 months, and 
the lack of early treatment may have contributed to 
the inconsistent improvements in symptoms relative 
to the MRI findings.
Material and methods
Search strategy
We conducted a comprehensive literature search of PubMed to 
identify studies that reported neurosarcoidosis with CDI. A search 
of the PubMed database was performed using the terms ‘neuro-
sarcoidosis’ or ‘central nervous system sarcoidosis’ and ‘diabetes 
insipidus’ to identify any articles published through March 2019.
Study selection
Original case reports that included the following data were in-
cluded in the present review: 1) age and sex; 2) first symptoms; 3) 
duration of polydipsia or polyuria; 4) affected organs (lungs, eyes, 
or other organs); 5) anterior pituitary function; 6) brain MRI find-
ings (abnormalities or loss of high signal intensity of the posterior 
lobe of the pituitary); 7) histological findings; 8) treatment; and 9) 
clinical course (brain MRI findings and CDI improvement). Review 
articles and articles written in languages other than English were 
excluded. After we identified 98 articles, we determined that 13 
articles (including 20 patients) were eligible.
Results
Table I provides a summary and Table II provides 
a detailed list of the characteristics of the 20 patients 
who were diagnosed with neurosarcoidosis with 
CDI. The patients included 12 men [8–12, 14, 15, 17] 
and eight women [7, 10, 13, 16, 18, 19], with a mean 
age of 33 years. The first symptom was polyuria in 13 
patients [7–9, 11–17] and polydipsia in eight patients 
[7–9, 11–15]. The mean duration from disease onset to 
diagnosis was 3.4 months. Isolated neurosarcoidosis 
was reported in four patients [7, 8, 10, 12]. Brain MRI 
showed abnormal findings in the pituitary stalk in 10 
patients [7, 8, 10–13, 16], abnormal findings in the pitu-
itary gland in nine patients [8–13, 15], and loss of high 
intensity of the posterior lobe of the pituitary in nine 
patients [8, 9, 11–13]. Twelve patients were diagnosed 
through biopsies of the lymph nodes [8, 10, 14, 16, 17], 
lungs [8–10], and skin [13,15], while only one patient 
underwent a brain biopsy [8].
Table III provides a detailed list of the clinical treat-
ments, brain MRI findings, and outcomes of patients 
with neurosarcoidosis and CDI. Steroid therapy was 
administered to 17 patients [8–12, 14–19], infliximab was 
administered to two patients [17, 19], cyclophosphamide 
was administered to one patient [10], and methotrexate 
was administered to one patient [19]. Desmopressin 
(1-desamino-8-D-arginine vasopressin) (DDAVP) was 
used to treat the symptoms of CDI in 19 patients [7–14, 
16–19]. Fourteen patients showed improvement in 
their abnormal brain MRI findings [8–13, 15–17], but no 
patients showed improvement in the loss of high signal 
intensity in the posterior lobe of the pituitary. One patient 
showed spontaneous improvement in CDI symptoms 
without the use of an immunosuppressive agent [13]. 
Five patients showed improvement in their anterior 
pituitary functions, and improvement in the MRI find-
ings were also recognised in these patients [8, 9, 11, 16].
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Untreated self-limiting cases and cases with atypical 
neurosarcoidosis have been reported [10, 13, 23]; addi-
tionally, several diseases can present with MRI findings 
that are similar to those observed for neurosarcoidosis 
[7]. Substantial experience and cautious judgment 
appear to be necessary for the accurate diagnosis of 
neurosarcoidosis in patients with CDI, which could 
also explain the inconsistencies observed between CDI 
symptoms and MRI findings.
The current review has several limitations. The 
number of reports included in the review was relatively 
small. Because brain biopsies were very rare (only one 
case in this review), most patients were clinically but not 
pathologically diagnosed. None of the reviewed studies 
Table I. Clinical diagnoses, treatments, and outcomes for patients with neurosarcoidosis and central diabetes insipidus
Diagnosis Treatments
Age, years 33 (10–77) Immunosuppressant (n = 20)
Sex, male 12 (60)   PSL 16 (80)
First manifestations (n = 20)   mPSL 2 (10)
  Polyuria 13 (65)   Hydrocortisone 2 (10)
  Polydipsia 8 (40)   Infliximab 2 (10)
Duration of polydipsia or polyuria (months) 3.4 (1–12)
  Cyclophosphamide 1 (5)
  Methotrexate 1 (5)
Lesion sites (n = 20) Endocrine (n = 20)
  Lungs 13 (65)   DDAVP 19 (95)
  Eyes 3 (15)   Thyroid hormone 3 (15)
  Isolated 4 (20)   Gonadotropin hormone 1 (5)
Anterior pituitary dysfunction (n = 20)
  PRL 12 (60) Symptoms and MRI findings
  LH 9 (45)   Brain MRI abnormality (n = 20)
  FSH 9 (45)     Improved 14 (70)
  ACTH 6 (30)     Not improved 3 (15)
  TSH 6 (30)     NR 3 (15)
  GH 4 (20)   Improvement of loss of high signal intensity* (n = 20)
  Panhypopituitarism 3 (15)     Improved 0 (0)
Brain MRI (n = 20)     No change 4 (20)
  Abnormality 18 (90)     NR 16 (80)
    Pituitary stalk 10 (50)   Symptoms of CDI (n = 20) 
    Pituitary gland 9 (45)     Improved 1 (5)
    Hypothalamus 5 (25)     Not improved 15 (75)
  Loss of high signal intensity*     NR 4 (20)
    Yes 9 (45)   Anterior pituitary dysfunction (n = 16)
    No 1 (5)     Improved 4 (20)
    NR 10 (50)     Not improved 4 (20)
Histology (n = 20)     NR 8 (40)
  Brain 1 (5)   Other neurological symptoms (n = 14)
  Others 11 (55)     Improved 7 (50)
    Lymph node 6 (30)     Not improved 3 (15)
    TBLB 3 (15)     NR 4 (20)
    Skin 2 (10)
Data are presented as the mean (range) or n (%); *posterior lobe of the pituitary gland; PRL — prolactin; LH — luteinising hormone; FSH — follicle stimulating 
hormone; ACTH — adrenocorticotropic hormone; TSH — thyroid-stimulating hormone; GH — growth hormone; MRI — magnetic resonance imaging; NR — not 
reported; TBLB — transbronchial lung biopsy; PSL — prednisolone; mPSL — methylprednisolone; DDAVP — 1-desamino-8-D-arginine vasopressin; CDI — central 
diabetes insipidus
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included a follow-up period that was long enough to 
demonstrate improvements in neurosarcoidosis with 
CDI.
Conclusion
During the clinical course of neurosarcoidosis and 
CDI, symptoms frequently do not improve even when 
improvements are observed in the brain MRI findings 
following treatment, which highlights the need for 
vigilance in clinical practice when assessing the prog-
ress of neurosarcoidosis and CDI. More studies with 
detailed pathological analyses and longer follow-up 
periods are necessary.
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